Fluvoxamine-associated oscillopsia and a role for personalized medication dosing.
A 60-year-old woman reported horizontal "shimmering" movement while reading crossword puzzles when using fluvoxamine, bupropion, quetiapine, lithium, and levothyroxine. This visual disturbance, likely oscillopsia, started after the fluvoxamine was added and waned as the fluvoxamine was tapered, disappearing after the drug was discontinued. Genetic testing to explore how the patient metabolizes these medications combined with YouScript® interaction analysis suggest that she may have had abnormally high plasma concentrations of fluvoxamine during this time. Oscillopsia may be a novel dose-dependent side effect of fluvoxamine. Genetic testing combined with YouScript has the potential to discover novel drug side effects, elucidate drug interactions and guide future prescribing decisions.
Eric L
EL
Singman
Brian
B
Hocum
Jithin
J
Yohannan
Virginia
V
Pearson
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects; D016642:Bupropion / Q000008:administration & dosage / Q000009:adverse effects; D003866:Depressive Disorder / Q000188:drug therapy; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D004347:Drug Interactions; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D015835:Ocular Motility Disorders / Q000139:chemically induced*; D057285:Precision Medicine; D000069348:Quetiapine Fumarate / Q000008:administration & dosage / Q000009:adverse effects
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion; D000069348:Quetiapine Fumarate; D016666:Fluvoxamine